Goldman Sachs Reiterates Buy Rating for ALS: Commodity Cycle Upturn and Attractive Valuation

Overview

This report is published by Goldman Sachs, updating the analysis on Australian Testing, Inspection, and Certification (TIC) company ALS Ltd (ALQ.AX). The core view is that as commodity momentum improves, ALS's cyclical leverage will continue to manifest. Although management has raised FY26 organic revenue guidance for commodities, market consensus remains conservative on FY27 growth acceleration. Through peer comparison and leading indicator analysis, Goldman Sachs reiterates its 'Buy' rating for ALS and sets a target price of A$28.00, considering its growth-adjusted valuation attractive among listed TIC peers.

Core views

Enhanced momentum in commodity business: While management raised FY26 organic revenue guidance for commodities to low-to-mid double-digit growth (+LDD-MDD%) in November 2025, market consensus has limited expectations for FY27 acceleration. Goldman Sachs believes this consensus is overly conservative. Cross-validation from peers shows Chrysos Corp reported strong sample volume growth; SGS and Bureau Veritas also demonstrated robust organic revenue growth in their April 2026 earnings, driven by gold, rare earth metals demand, and increased exploration spending. Life Sciences business meets expectations: Peer data indicates SGS and Eurofins achieved mid-single-digit (~MSD%) organic growth in Life Sciences-related segments. This aligns with Goldman Sachs's estimate of 4% organic growth for ALS's FY26 Life Sciences business (management guidance: 4-6%), suggesting stable but not explosive growth. Leading indicators point to active exploration: As a leading indicator for exploration activity, Imdex (IMD) saw its sensor, service, and SaaS revenue accelerate to 28% YoY growth in 3Q26 (25% in 2Q26). This acceleration reflects a shift from stable to active global exploration conditions, indicating a more favorable macro environment for ALS's commodity business in coming quarters. Attractive valuation: ALS currently trades at ~NTM EV/EBIT 17x, seemingly the highest among listed TIC peers. However, considering its higher expected growth rate (Goldman Sachs estimates CAGR at 15.7%, consensus at 14.1%), growth-adjusted EV/EBIT multiple is only 1.1-1.2x, below peer median (1.8x) and average (1.7x), showing high cost-effectiveness.

Analysis framework

Goldman Sachs adopts a combined method of 'peer cross-validation' and 'leading indicator analysis.' First, by reviewing earnings commentary from global TIC leaders like SGS, Bureau Veritas, and Eurofins, it confirms overall industry sentiment in commodity testing, supporting ALS's revenue growth logic. Second, it uses Imdex (IMD) sensor business growth as a leading indicator for global mineral exploration activity, inferring downstream demand sustainability for ALS from its acceleration. Finally, on valuation, it introduces a 'growth-adjusted valuation' (Growth-adjusted EV/EBIT) framework beyond absolute multiples, eliminating the illusion of valuation premium from high growth, concluding ALS is undervalued.

Methodology notes

• Valuation MethodEV/EBITDA valuation

  Growth-adjusted Valuation

  Simply comparing EV/EBIT multiples may ignore growth differences. This method divides valuation multiples by expected growth rate to derive valuation cost per unit growth. The report notes ALS has higher absolute multiples but lower relative valuation after division by high growth rate, making it more attractive.

• Industry Analysis FrameworkUpstream-Midstream-Downstream Transmission

  Upstream Exploration Activity Transmitting to Downstream Testing Services

  The report uses Imdex (upstream exploration equipment and services) revenue growth as a leading indicator to predict future demand for ALS (downstream testing services). The logic is increased exploration activity directly drives subsequent sample testing demand, with a time lag but consistent direction.

• Valuation MethodDCF Discounted Cash Flow

  Weighted Average of DCF and Relative Valuation

  Target price is determined by DCF valuation (50% weight) and NTM EV/EBIT relative valuation (50% weight). DCF assumes WACC of 7.9% and perpetual growth rate of 2.5%, reflecting rigorous consideration of long-term cash flow stability and capital cost.

Asset mapping & comparison

Structured mapping from thesis to named assets (strengths, weaknesses, peers, risks).

• ALS Ltd (ALQ.AX)

  Direct beneficiary, higher exposure to commodity testing business, directly benefiting from increased exploration activity

  Strengths

  High growth expectations (CAGR ~15%), cheap growth-adjusted valuation, solid industry position

  Weaknesses

  Higher absolute valuation multiples among peers may trigger short-term fear of heights

  Comparison

  Compared to peers like SGS and Bureau Veritas, ALS has higher expected growth rates and lower growth-adjusted valuation

  Risks

  Commodity cycle volatility, exploration spending falling short of expectations

Key data

• Target PriceA$28.00Based on weighted average of DCF and EV/EBIT
• Current PriceA$22.19Recent price as of report publication
• NTM EV/EBIT~17xALS current trading multiple
• Growth-adjusted EV/EBIT1.1x - 1.2xBelow peer median 1.8x, showing valuation advantage
• FY26 Life Sciences Organic Growth Estimate4%Within Goldman Sachs estimate range, management guidance 4-6%
• IMD 3Q26 Sensor Revenue Growth+28% YoYFurther acceleration from 25% in 2Q26, reflecting active exploration
• DCF Assumption WACC7.9%Weighted average cost of capital
• DCF Assumption Perpetual Growth Rate2.5%Terminal growth assumption

Impact & implications

The report believes global commodity exploration recovery will provide sustained revenue momentum for ALS, especially its high-margin commodity testing segment. Market conservatism on FY27 growth expectations creates a gap; subsequent performance realization may drive valuation repair. For investors, ALS is not only a defensive TIC stock but also offers procyclical offensive attributes.

Risks

• Uncertain timing, speed, and duration of commodity upturn
• Commodity testing volume and pricing pressure
• Global macroeconomic slowdown leading to exploration spending cuts

What to watch

• Whether FY27 commodity organic revenue growth accelerates as Goldman Sachs expects
• Sustainability of global mineral exploration indicators (e.g., Imdex sensor business growth)
• Whether ALS Life Sciences business can maintain 4-6% guidance range